PET developer Positron has joined forces with Neusoft Medical Systems on a deal that gives Neusoft the right to distribute Positron's new PET/CT scanner in North America.
The companies will work together on Positron's new PET/CT scanner, which is based on the existing Neusoft NeuWise PET/CT system. The deal covers manufacturing, distribution, and continued R&D on the system, and the companies will work together on submitting a 510(k) application in the second quarter of 2022 with the U.S. Food and Drug Administration.
The agreement is designed to enable the companies to further develop PET/CT technology and services in nuclear cardiology, while also expanding into oncology.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
